Overview

• US biopharma's Q1 net product revenue rose quarter-over-quarter as ZEVASKYN adoption increased

• Q1 loss per share beat analyst expectations

• Co has $168.3M in cash, cash equivalents and short-term investments as of March 31, 2026

• Company in-licensed novel T-cell therapy asset and deprioritized ophthalmology programs

Outlook

• Abeona expects to file an IND and start first-in-human ABO-701 studies in H2 2027

• Company plans to maintain focus on commercializing ZEVASKYN while developing ABO-701

Result Drivers

• ZEVASKYN ADOPTION - Higher Q1 product revenue driven by increased ZEVASKYN patient treatments and broader access

• QTC NETWORK EXPANSION - Activation of two new qualified treatment centers expanded patient access to ZEVASKYN

• COMMERCIAL TRANSITION COSTS - SG&A expenses rose due to commercial transition post-ZEVASKYN approval, including personnel and training costs

Company press release: ID:nGNX9ph0wZ

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy."

• Wall Street's median 12-month price target for Abeona Therapeutics Inc is $20.00, about 252.1% above its May 12 closing price of $5.68

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.